Plasma exosomes impair microglial degradation of α‐synuclein through V‐ATPase subunit V1G1
Yunna Li,Yiming Wang,Liang Kou,Sijia Yin,Xiaosa Chi,Yadi Sun,Jiawei Wu,Zongjie Jin,Qiulu Zhou,Wenkai Zou,Tao Wang,Yun Xia
DOI: https://doi.org/10.1111/cns.14738
2024-05-05
CNS Neuroscience & Therapeutics
Abstract:Plasma‐derived exosomes from patients with PD contain toxic α‐syn and PD‐exo downregulates lysosomal V1G1 expression; PD‐exo alternated the amount, morphology, and distribution of lysosomes in microglia and impaired the activity of hydrolytic enzymes in the lumen; PD‐exo augmented the accumulation of pathological α‐syn within microglia and induced NLRP3‐mediated neuroinflammation; and V1G1 deficiency impaired lysosomal function, leading to further aggregation of α‐syn in microglia and inflammation. Introduction Microglia are the main phagocytes in the brain and can induce neuroinflammation. Moreover, they are critical to alpha‐synuclein (α‐syn) aggregation and propagation. Plasma exosomes derived from patients diagnosed with Parkinson's disease (PD‐exo) reportedly evoked α‐syn aggregation and inflammation in microglia. In turn, microglia internalized and released exosomal α‐syn, enhancing α‐syn propagation. However, the specific mechanism through which PD‐exo influences α‐syn degradation remains unknown. Methods Exosomes were extracted from the plasma of patients with PD by differential ultracentrifugation, analyzed using electron microscopy (EM) and nanoparticle flow cytometry, and stereotaxically injected into the unilateral striatum of the mice. Transmission EM was employed to visualize lysosomes and autophagosomes in BV2 cells, and lysosome pH was measured with LysoSensor Yellow/Blue DND‐160. Cathepsin B and D, lysosomal‐associated membrane protein 1 (LAMP1), ATP6V1G1, tumor susceptibility gene 101 protein, calnexin, α‐syn, ionized calcium binding adaptor molecule 1, and NLR family pyrin domain containing 3 were evaluated using quantitative polymerase chain reaction or western blotting, and α‐syn, LAMP1, and ATP6V1G1 were also observed by immunofluorescence. Small interfering ribonucleic acid against V1G1 was transfected into BV2 cells and primary microglia using Lipofectamine® 3000. A PD mouse model was established via injection with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) into mice. A lentiviral‐mediated strategy to overexpress ATP6V1G1 in the brain of MPTP‐treated mice was employed. Motor coordination was assessed using rotarod and pole tests, and neurodegeneration in the mouse substantia nigra and striatum tissues was determined using immunofluorescence histochemical and western blotting of tyrosine hydroxylase. Results PD‐exo decreased the expression of V1G1, responsible for the acidification of intra‐ and extracellular milieu. This impairment of lysosomal acidification resulted in the accumulation of abnormally swollen lysosomes and decreased lysosomal enzyme activities, impairing lysosomal protein degradation and causing α‐syn accumulation. Additionally, V1G1 overexpression conferred the mice neuroprotection during MPTP exposure. Conclusion Pathogenic protein accumulation is a key feature of PD, and compromised V‐type ATPase dysfunction might participate in PD pathogenesis. Moreover, V1G1 overexpression protects against neuronal toxicity in an MPTP‐based PD mouse model, which may provide opportunities to develop novel therapeutic interventions for PD treatment.
pharmacology & pharmacy,neurosciences